Sacral Nerve Modulation (SNM) is a minimally-invasive technology indicated for overactive bladder (OAB). SNM efficacy has been widely demonstrated yet its cost-effectiveness in the UK is unknown. The cost-effectiveness of SNM in patients with refractory idiopathic OAB with urinary incontinence (OAB-wet) was compared to optimal medical therapy (OMT), Botulinum Toxin A (BoNT-A) and PTNS from the UK NHS perspective. METHODS: A published Spanish Markov model was adapted to current UK practice based on existing data and clinical expert advice. Treatment success was defined as Ͼ50% improvement in OAB-wet symptoms. Health care resource use included pre-,peri-, and post-procedure; drugs; follow-ups and adverse events. Both SNM using testing with tined-lead (SNMtined-lead) and PNE (SNM-PNE) were evaluated. Incremental-cost-effectivenessratios (ICER;costs per quality-adjusted-life-year)were calculated for SNM vs. OMT and vs. BoNT-A (10yrs), and SNM vs, PTNS (5yrs); with uni-variate sensitivity analyses. RESULTS: At 10 years, the cumulative costs of SNM-tined-lead, SNM-PNE, BoNT-A and OMT were £22,052, £19,952, £18,477, £11,918, respectively; PTNS 5-year cumulative costs were £17,915.The QALYs for SNM-tined-lead, SNM-PNE, 6.64, 6.35 and 5.45 (10yrs), respectively, and 3.44 for PTNS (5yrs). ICERs were £7,608 and £7,356 for SNM-tined-lead vs. BoNT-A, and vs OMT (10yrs), respectively; SNM-tined-lead and SNM-PNE were dominant (less costly and more effective) compared to PTNS (5 years). SNM-tined-lead was cost-effective vs.SNM-PNE. ICERs were most sensitive to BoNT-A efficacy and costs, but results were generally robust. CONCLUSIONS: SNM in patients with OAB-wet provides additional quality of life improvement with higher initial costs for SNM that are offset by a reduction in follow-up costs over time. This produces ICERs that are clearly below the threshold generally considered for cost-effectiveness in the UK. SNM represents value for money compared to OMT, BoNT-A and PTNS, and may be considered the preferred treatment option in the UK. 
PMD56

COST-EFECTIVENESS ANALYSIS COMPARING THE APPLICATION OR NOT OF WHOLE BRAIN IRRADIATION BEFORE STEREOTECTIC RADIOSURGERY FOR THE TREATMENT OF ONE TO FOUR BRAIN METASTASES, ACCORDING TO BRAZILIANS THIRD-PARTY PRIVATE PAYER'S PERSPECTIVE
OBJECTIVES:
In patients with one to four brain metastasis, if diameter Ͻ 4 cm, the standard treatment is whole brain irradiation (WBI) followed by stereotactic radiosurgery (SRS). There is growing interest on the delivery of isolated SRS, aiming to reduce side effects of WBI, despite a higher risk of intra-cerebral recurrences. The objective of this study was to compare the cost-effectiveness of those two strategies, under Brazilians third-part payers' perspective. METHODS: A meta-analysis of summary data, including all phase III prospective trails that compared SRS to WBIϩSRS, was performed. Data about recurrence management, dependant of on the lesion size, as well as of previous delivered treatment, were also extracted. Costs were estimated based on charges accordingly to Brazilian Health Care reimbursement rates for the private system (CBHPM). Only directs costs were considered, and were expressed in Brazilian Reais (BRL). A probabilistic sensitivity analysis was conducted to evaluate the robustness of the results. The perspective was that from the Brazilian Third Party payer. RESULTS: Three phase III prospective trials have been selected, including 467 patients. Once there was no difference in overall survival, effectiveness was evaluated according to local control. After two years of follow up, 78% [64.2-87 .4%] of the SRS patients and 53% [47-57%] of the WBIϩSRS patients have recurred. The incremental cost-effectiveness ratio (ICER) comparing WBIϩSRS to SRS was of 7.489,60 BRL/year without cerebral recurrences. Sensitivity analysis showed that ICER remains acceptable under a wide range of assumptions . CONCLUSIONS: Results suggested that WBIϩSRS might be considered as a cost-effective strategy in patients with up to 4 brain metastases. Once no detrimental survival effect have been shown, SRS can be cost-savings for Brazilians third-party payers, but patients need to be aware of the risks involved in not delivering WBI. 
PMD57 THE COSTS-EFFECTIVENESS OF COBAN 2 FOR THE TREATMENT OF VENOUS LEG ULCERS IN THE NETHERLANDS
OBJECTIVES:
To assess the cost-effectiveness of 3M™ Coban™2 Layer Compression System (Coban 2) for the treatment of venous leg ulcers in the Dutch health care setting. METHODS: The health economic evaluation consists of a cost-effectiveness analysis. A Markov model was developed in order to determine the costeffectiveness of Coban 2, which was based on different health states and allowed transitions between these states. Upon initiation of the compression system Coban 2, the patient is supposed to have an ulcer. Over time, the ulcer may heal, but it may also recur. The treatment with Coban 2 is compared with traditional treatment (Short Stretch Bandages (SSB)). The primary perspective of the study is that of the Dutch insurer in 2012. The actual costs, which are included in the study, are product costs and treatment costs. Clinical probabilities on healing and recurrence are derived from clinical published literature. RESULTS: The use of Coban 2 leads to a total cost of € 600 compared to € 2,663 for traditional care, which leads to cost saving of € 2,063 per patient over a period of 1 year. 
This study evaluated the cost-effectiveness of three leprosy case detection methods in Northern Nigeria to identify the most cost-effective approach to new case detection for improved leprosy control in Nigeria. METHODS: A crosssectional study was carried out to evaluate the additional benefits of using several case detection methods in addition to routine practice in two north-eastern states of Nigeria. Primary and secondary data were collected from routine practice records and the Nigerian Tuberculosis and Leprosy Control Programme of 2009. Methods evaluated were Rapid Village Survey (RVS), Household Contact Examination (HCE) and Traditional Healers incentive method (TH). Effectiveness was measured as number of new leprosy cases detected and cost-effectiveness was expressed as cost per case detected. Costs were measured from both providers' and patients' perspectives. Additional costs and effects of each method were estimated by comparing each method against routine practise and expressed as incremental cost-effectiveness ratio (ICER). All costs were converted to the US Dollar at the 2010 exchange rate. Univariate sensitivity analysis was used to evaluate uncertainties around the ICER. RESULTS: The ICER for HCE was $142 per additional case detected at all contact levels and it was the most cost-effective method. At ICER of $194 per additional case detected, THs method detected more cases at a lower cost than the RVS which was not cost-effective at $313 per additional case detected. Sensitivity analysis showed that varying the proportion of shared costs and subsistent wage for valuing unpaid time did not significantly change the results. CONCLUSIONS: Complementing routine practice with household contact examination is the most cost-effective approach to identify new leprosy cases and we recommend that, depending on acceptability and feasibility, this intervention is introduced for improved case detection in Northern Nigeria. 
PMD60 THE COSTS-EFFECTIVENESS OF 3M™ COBANTM 2 LAYER COMPRESSION SYSTEM (COBAN 2) FOR THE TREATMENT OF LYMPHOEDEMA IN THE NETHERLANDS
OBJECTIVES:
To assess the cost-effectiveness of 3M™ CobanTM2 Layer Compression System (Coban 2) for the treatment of lymphoedema in the Dutch health care setting. METHODS: The health economic evaluation consists of a cost-effectiveness analysis. A decision tree model was developed in order to determine the cost-effectiveness of Coban 2. The entry point of the model consists of patients with lymphoedema requiring treatment with compression bandages. The treatment with Coban 2 is compared with traditional treatment (Short Stretch Bandages). The primary perspective of the study is that of the Dutch insurer in 2012. The actual costs, which are included in the study, are product costs and treatment costs. RESULTS: The use of Coban 2 leads to a mean total cost of € 528 compared to € 630 for traditional care, which leads to a cost saving of € 102 per patient. The effectiveness for Coban 2 is higher because of a shorter treatment period, which leads to a reduction of the negative impact on Quality of life by lymphoedema. CONCLUSIONS: The use of Coban 2 versus traditional treatment is cost saving for each treatment period with a higher effectiveness, due to shorter treatment duration and improvement in Quality of Life. As a consequence the use of Coban 2 leads to a positive impact on the total health care budget. 
PMD61 COST-EFFECTIVENESS OF POSITRON EMISSION TOMOGRAPHY IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: A SYSTEMATIC REVIEW
OBJECTIVES:
Functional imaging with positron emission tomography (PET) is a promising non-invasive modality in the clinical management of squamous cell carcinoma of the head and neck (SCCHN). Currently, there is limited evidence that points to the potential cost-effectiveness of PET in this setting. The objective of this study was to assess the methodological quality of cost-effectiveness analyses (CEAs) of PET in SCCHN. METHODS: A systematic literature review was performed focusing on CEAs of PET in SCCHN using MEDLINE, EMBASE, NHS EED and the CEA Registry. Studies were screened according to a priori eligibility criteria. The methodological quality of the primary clinical studies was examined by QUality Assessment of Diagnostic Accuracy Studies checklist. CEAs were critically appraised using the Drummond checklist. RESULTS: A total of seven studies met the inclusion criteria. PET or computed tomography (CT) integrated with PET was assessed in two indications: detection of recurrent disease and screening for metastasis. In each indication, PET strategy ranged from likely to be cost-effective (in four studies) to A355 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5
